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Abstract
Typical methods used for encapsulating antisense oligodeoxynucleotides (ODN) and plasmid DNA in lipid vesicles result
in very low encapsulation efficiencies or employ cationic lipids that exhibit unfavorable pharmacokinetic and toxicity
characteristics when administered intravenously. In this study, we describe and characterize a novel formulation process that
utilizes an ionizable aminolipid (1,2-dioleoyl-3-dimethylammonium propane, DODAP) and an ethanol-containing buffer
system for encapsulating large quantities (0.15^0.25 g ODN/g lipid) of polyanionic ODN in lipid vesicles. This process
requires the presence of up to 40% ethanol (v/v) and initial formulation at acidic pH values where the DODAP is positively
charged. In addition, the presence of a poly(ethylene glycol)-lipid was required during the formulation process to prevent
aggregation. The ‘stabilized antisense-lipid particles’ (SALP) formed are stable on adjustment of the external pH to neutral
pH values and the formulation process allows encapsulation efficiencies of up to 70%. ODN encapsulation was confirmed by
nuclease protection assays and 31P NMR measurements. Cryo-electron microscopy indicated that the final particles consisted
of a mixed population of unilamellar and small multilamellar vesicles (80^140 nm diameter), the relative proportion of which
was dependent on the initial ODN to lipid ratio. Finally, SALP exhibited significantly enhanced circulation lifetimes in mice
relative to free antisense ODN, cationic lipid/ODN complexes and SALP prepared with quaternary aminolipids. Given the
small particle sizes and improved encapsulation efficiency, ODN to lipid ratios, and circulation times of this formulation
compared to others, we believe SALP represent a viable candidate for systemic applications involving nucleic acid
therapeutics. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Nucleic acid-based therapeutics, such as antisense
oligodeoxynucleotides (ODN), ribozymes, and plas-
mid DNA, o¡er the potential to speci¢cally target
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diseased cells at the molecular level. However, these
large polyanionic macromolecules possess several in-
herent characteristics that restrict their pre-clinical
and clinical utility for the therapy of chronic dis-
eases, including cost and production of clinical grade
material [1], degradation and inactivation by nucle-
ases in plasma and cells [2], poor intracellular deliv-
ery [3,4], rapid plasma elimination [5,6], as well as
renal and dose-limiting hemodynamic toxicities [7^9].
For antisense ODN, which are furthest along in clin-
ical development, nuclease sensitivity has been mini-
mized through chemical modi¢cations to the nucleic
acid backbones and/or sugars [10], while hemody-
namic toxicities have been reduced through the use
of repeated, slow infusions (2 h) or continual infu-
sion protocols of up to 21 days [11]. However, it
would be expected that encapsulation of antisense
ODN and other DNA- and RNA-based therapeutics
in lipid vesicles would greatly reduce these concerns
and improve the utility of these molecules without
the need for chemical modi¢cation. This will be par-
ticularly critical for larger DNA and RNA agents
such as ribozymes and plasmids on which modi¢ca-
tions would be increasingly more complicated and
costly.
Conventional and sterically stabilized liposomes
have been used extensively to increase the therapeutic
index of a variety of drugs by changing their phar-
macokinetic and pharmacodynamic characteristics
[12^14]. Lipid-based formulations of vincristine,
doxorubicin, daunorubicin and amphotericin B
have all demonstrated signi¢cant clinical improve-
ment over the free compounds [12,13,15,16]. Re-
cently, considerable e¡ort has been applied to formu-
lating DNA- and RNA-based therapeutics in lipid
delivery systems in an attempt to realize similar ben-
e¢ts [3,17,18]. The development of liposome and lipid
delivery systems for nucleic acid-based therapeutics
for systemic therapy, however, has been limited by
two principal factors ^ low encapsulation e⁄ciency
(6 10%) and drug to lipid ratios (0.001^0.1, w/w)
in neutral lipid formulations, and pharmacokinetic
and toxicity issues associated with the use of cationic
lipid.
In an e¡ort to improve encapsulation e⁄ciencies,
several approaches have been employed to entrap
antisense ODN in lipid vesicles. These include direct
rehydration of lipid ¢lms in the presence of nucleic
acid, a minimal volume entrapment (MVE) tech-
nique, detergent dialysis, reverse-phase encapsula-
tion, chemical modi¢cation to increase the lipophilic-
ity of ODN, and the use of cationic lipids (reviewed
in [19^21]). The inclusion of cationic lipids in lipid
formulations improves the association with polya-
nionic nucleic acids. Moreover, the presence of a
net positive surface charge on nucleic acid/lipid par-
ticles facilitates binding and uptake by cells in vitro
[3]. However, in using cationic lipids it is often not
clear whether all of the nucleic acid is encapsulated
inside a bilayer envelope or whether small complexes
of cationic liposome/nucleic acid are formed. Fur-
thermore, when delivery systems bearing a net cat-
ionic charge are administered intravenously (i.v.),
they exhibit rapid plasma clearance, distribute into
lung, liver and spleen [22^24], and often exhibit liver
and hemodynamic toxicities, such as activation of
complement and prolongation of clotting times [25^
27]. Therefore, there is a growing need to mask or
reduce the cationic lipid content in delivery systems.
In this study, we describe a novel process that utilizes
an ionizable aminolipid to facilitate e⁄cient encap-
sulation of antisense ODN in lipid vesicles that can
subsequently be rendered neutral at physiological
pH. Using this approach, we address the issues of
improving encapsulation e⁄ciencies and drug to lipid
ratios, as well as reducing the net cationic lipid con-
tent of the vesicles, resulting in improved pharmaco-
kinetics of the formulation relative to delivery sys-
tems containing quaternary aminolipids or cationic
liposome/ODN complexes.
2. Materials and methods
2.1. Lipids and chemicals
Distearoylphosphatidylcholine (DSPC), egg phos-
phatidylcholine (EPC), and dioleoyldimethylammo-
nium chloride (DODAC) were purchased from
Northern Lipids, Inc. (Vancouver, B.C., Canada).
1,2-Dioleoyl-3-dimethylammonium propane (DO-
DAP) was obtained from Avanti Polar Lipids, Inc.
(Alabaster, AL, USA). Cholesterol (CH) was pur-
chased from Sigma-Aldrich (Oakville, Ont., Canada).
Radiolabeled cholesterylhexadecylether (CHE) was
purchased from Mandel Scienti¢c (Guelph, Ont.,
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N-arachidoylsphingosine (PEG-CerC20) were synthe-
sized as described elsewhere [28]. All lipids were
s 99% pure.
2.2. Antisense ODN
All ODN were synthesized with phosphorothioate
(PS) backbone chemistry. The 5P^3P sequences and
mRNA targets of these ODN are as follows:
EGFR (human epidermal growth factor receptor),
CCGTGGTCATGCTCC [29]; c-myc (human/mur-
ine c-myc proto-oncogene), TAACGTTGAGGGG-
CAT [30]; hICAM (human intercellular adhesion
molecule-1), GCCCAAGCTGGCATCCGTCA [31];
mICAM (murine intercellular adhesion molecule-1),
TGCATCCCCCAGGCCACCAT [32]; and sICAM
(scrambled control for mICAM), TCGCATC-
GACCCGCCCACTA [32]. Radiolabeled ([3H] and
[35S]) ODN were purchased from TriLink BioTech-
nologies, Inc. (San Diego, CA, USA). Early experi-
ments were conducted using ICAM-1 sequences pro-
vided by Dr. Frank Bennett of ISIS Pharmaceuticals
(Carlsbad, CA, USA). Later work employed ODN
purchased from Hybridon Specialty Products (Wor-
cester, MA, USA). Extinction coe⁄cients were calcu-
lated from the pairwise extinction values for individ-
ual nucleotides, taking into account nearest neighbor
interactions. The purity of all ODN was determined
by the individual suppliers using high performance
liquid chromatography (HPLC) and/or capillary gel
electrophoresis.
2.3. Preparation of stabilized antisense-lipid particles
(SALP)
To determine the in£uence of ethanol on encapsu-
lation of ODN, lipid ¢lms were hydrated with solu-
tions of ODN containing varying amounts of ethanol
in citrate bu¡er, pH 4.0. The resulting solution was
then extruded through three stacked 100 nm polycar-
bonate ¢lters (Osmonics, Livermore, CA, USA) us-
ing a thermobarrel extruder (Lipex Biomembranes,
Vancouver, B.C., Canada) maintained at approxi-
mately 65‡C [33]. In the presence of ethanol, extru-
sion was rapid and required low nitrogen pressures;
therefore, three ¢lters were used to ensure a homo-
geneous particle size distribution of the ¢nal vesicles.
For all subsequent studies, lipid stock solutions were
prepared in 100% ethanol. Typically, 13 Wmol (V10
mg) of total lipid (0.4 ml total volume) was added to
a glass tube containing trace amounts of [14C]CHE.
ODN (2 mg by A260) and trace amounts of [3H]ODN
were dissolved in 0.6 ml of 300 mM citric acid, pH
4.0 in a separate tube. The ODN and lipid solutions
were warmed for 2^3 min to 65‡C and the lipids were
slowly added to the ODN, while mixing constantly.
The mixture was passed 10 times through three
stacked 100 nm polycarbonate ¢lters as described
above. The preparation was dialyzed (12^14 kDa
cuto¡) against 300 mM citrate bu¡er, pH 4.0 for
approximately 1 h to remove excess ethanol; then
further dialyzed against HBS (20 mM HEPES,
145 mM NaCl, pH 7.6) for 12^18 h to remove the
citrate bu¡er, neutralize the DODAP and release any
ODN that was associated with the surface of the
vesicles. Non-encapsulated ODN was removed by
DEAE-Sepharose CL-6B column chromatography.
The mean diameter and size distribution of SALP
was determined using a NICOMP Model 370 Sub-
micron particle sizer, and was typically 110 þ 30 nm.
A typical 1.0 ml formulation consisted of 13 Wmol
(V10 mg) total of DSPC/CH/DODAP/PEG-CerC14
(25/45/20/10, mol/mol/mol/mol) and 2 mg of ODN in
a ¢nal solution containing 180 mM citrate, pH 4.0
and 40% ethanol (v/v). All subsequent references to
the mol% of speci¢c lipid components of the formu-
lation are made with respect to total lipid molar
ratios. Encapsulation e⁄ciencies were calculated as
the ratio of the initial and ¢nal ODN to lipid ratios,
multiplied by 100. This was done to minimize the
impact of mechanical losses on the absolute recovery
of ODN and lipid in small sample sizes. In larger
volume formulations, mechanical losses were negli-
gible and encapsulation e⁄ciencies were comparable
to absolute ODN recoveries.
2.4. HPLC analysis of lipids
Lipid concentrations and mol ratios were deter-
mined by HPLC on a Beckman System Gold 128
apparatus equipped with an evaporative light scatter-
ing detector (SEDEX 55). Separations were per-
formed on a 2.0 mmU150 mm, 5 Wm Ultrasphere
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cyanopropyl column (Beckman Instruments). The
mobile phase consisted of solvent A (99.8% chloro-
form and 0.2% tri£uoroacetic acid) and solvent B
(90% isopropyl alcohol, 9.8% distilled water and
0.2% tri£uoroacetic acid), ¢ltered through a 0.5 Wm
¢lter. Aliquots (V300 Wg total lipid) of lipid formu-
lations were extracted in HBS/chloroform/methanol
(1:1:0.3, v/v/v). Individual lipid standards (50^
500 Wg) were prepared in chloroform to a ¢nal vol-
ume of 1.0 ml and extracted in HBS (1.0 ml) as
described above. The organic phase was analyzed
and linear standard curves were generated for each
lipid component in the formulation. Extraction re-
coveries were greater than 95% for all lipid compo-
nents. Accuracy bias was less than 5%.
2.5. Nuclease protection assays
Free or encapsulated ODN was incubated at 55‡C
with excess fungal S1 nuclease (100 U nuclease/Wg
ODN) according to the manufacturer’s instructions
(Gibco-BRL). In some instances, samples were incu-
bated with Triton X-100 (1% ¢nal concentration) to
solubilize the lipid vesicles. At various times, aliquots
were removed, placed in proteinase K bu¡er (10 mM
Tris, pH 8.0, 100 mM NaCl, 25 mM EDTA, 0.5%
SDS and 1 mg/ml proteinase K) and incubated at
50‡C for 1 h. Samples were added to an equal vol-
ume of stop bu¡er (93.6% formamide, 20 mM
EDTA, 0.05% bromophenol blue) and analyzed on
a denaturing 20% PAGE gel containing 7 M urea.
Visualization was facilitated using SYBR Green I
nucleic acid gel stain (Molecular Probes).
2.6. 31P nuclear magnetic resonance (NMR)
spectroscopy
31P NMR spectra were obtained by employing a
Bruker MSL200 spectrometer operating at 81 MHz.
Free induction decays (FIDs) corresponding to
800 scans were obtained by using a 2.8 Ws 50‡ pulse
with a 3 s interpulse delay and a spectral width of
20 000 Hz on a 2.0 ml sample in a 10 mm probe. No
proton decoupling was used. An exponential multi-
plication corresponding to 25 Hz of line-broadening
was applied to the FIDs prior to Fourier transfor-
mation. The chemical shift is referenced to external
85% phosphoric acid (H3PO4). In some instances,
ammonium acetate (150 mM) was added to the ex-
terior of SALP and the pH was adjusted to 7.4 with
NaOH. Ammonium acetate equilibrates the interior
and exterior pH of the vesicles. In designated spectra,
5 mM MnSO4 was added to the exterior of the
vesicles as a membrane impermeable paramagnetic
line-broadening agent that quenches the signals of
all accessible phosphate groups, including phospho-
lipids and ODN.
2.7. Cryo-electron microscopy
A single drop of bu¡er containing SALP was ap-
plied to a standard electron microscopy grid with a
perforated carbon ¢lm. Excess liquid was removed
by blotting, leaving a thin layer of the suspension
covering the holes of the carbon ¢lm. The grid was
rapidly frozen in liquid ethane, resulting in vesicles
embedded in a thin ¢lm of amorphous ice. Images of
the vesicles in the ice were obtained under cryogenic
conditions at a magni¢cation of 50 000 and a defocus
of 31.5 microns using a Gatan cryo-holder in a Phi-
lips CM200 FEG electron microscope.
2.8. Mice
Female, ICR mice (7^9 weeks) were purchased
from Harlan-Sprague Dawley (Indianapolis, IN,
USA) and were quarantined for 1 week prior to
use. All studies were conducted in accordance with
the guidelines established by the Canadian Council
on Animal Care (CCAC).
2.9. Plasma clearance of SALP
For pharmacokinetic studies, SALP formulations
containing PS ODN labeled by incorporation of a
[3H]thymidine base or 35S label in the PS backbone
were concentrated to approximately 12.5 mg/ml total
lipid using a hand-held dia¢ltration apparatus (A/G
Technology Corp., Needham, MA, USA) attached to
10 cc syringes. Samples of free or encapsulated
[3H]ODN were administered i.v. via the lateral tail
vein of ICR mice at a dosing volume of 10 ml/kg.
Lipid and ODN doses were 100 and 15 mg/kg body
weight (unless otherwise indicated), representing an
ODN to lipid ratio of 0.15, weight of ODN/weight of
total lipid. At various times, mice were anesthetized
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with ketamine/xylazene, and blood was collected by
cardiac puncture prior to euthanasia. Plasma was
collected and analyzed for radioactivity using stan-
dard liquid scintillation techniques. No signi¢cant
di¡erences in the circulation pro¢les were observed
over 24 h using the di¡erent radiolabels.
3. Results
3.1. Encapsulation of PS ODN in SALP
It is relatively straightforward to passively encap-
sulate anionic antisense ODN in the aqueous space
of conventional lipid vesicles [20,21,34]. However, to
achieve even modest encapsulation e⁄ciencies of 5^
10% in a population of large unilamellar vesicles
(LUV) with a mean diameter of 100 nm, extreme
concentrations of lipid and ODN must be employed.
This makes formulation di⁄cult, time consuming
and wasteful. The inclusion of 1^20 mol% cationic
lipid improves the association of anionic ODN and
plasmid DNA with vesicles through electrostatic in-
teractions, but when these systems are administered
i.v. they are rapidly eliminated from the circulation
[22^24,35] and exhibit poor accumulation at disease
sites, such as tumors and sites of in£ammation
[36,37]. Consequently, it was determined that ioniz-
able cationic lipids might be a better choice in that
formulations could be made at acidic pH, when the
majority of the lipid was cationic, but the resulting
delivery system would be charge ‘neutral’ when ad-
ministered at physiological pH.
DODAP was employed as an ionizable cationic
lipid as it exhibits an apparent pK of 6.6 in lipid
bilayer systems [38]. Encapsulation relying on elec-
trostatic interactions between ODN and cationic lip-
id can therefore occur at acidic pH values (i.e. pH
4.0), whereas subsequent adjustment of the external
pH to neutral pH values should result in a neutral
surface charge on the resulting particles. In order to
minimize aggregation and fusion between particles
during the formulation process, PEG-CerC14, a steric
barrier lipid, was included in the formulation. Initial
studies were conducted using a lipid mixture of
DSPC, CH, DODAP and PEG-CerC14 (25/45/20/
10, mol/mol/mol/mol). A dried lipid ¢lm was hy-
drated with an aqueous solution of PS ODN in
300 mM citrate bu¡er, pH 4.0, and the resulting lipo-
somes sized to 100 nm diameter vesicles by extrusion
at 65‡C. The external bu¡er was exchanged for bu¡-
ered saline (pH 7.6) to neutralize the positive charge
due to DODAP. The vesicles were subsequently
passed through an ion-exchange column to remove
residual ODN. This process yielded an encapsulation
e⁄ciency of approximately 30%. However, the extru-
sion process was slow and as much as 30% of both
the starting lipid and antisense ODN was lost be-
cause of the formation of ODN/lipid aggregates
that were trapped on the ¢lters.
3.2. In£uence of ethanol on encapsulation of ODN
In an e¡ort to improve the encapsulation e⁄ciency
and reduce losses during extrusion, ethanol was
Fig. 1. In£uence of ethanol on ¢nal encapsulation e⁄ciency (A)
and sample recoveries during extrusion (B) of SALP. Lipid
¢lms composed of a 10 mg (total lipid) mixture of DSPC/CH/
DODAP/PEG-CerC14 (25/45/20/10, mol/mol/mol/mol) were hy-
drated with 2 mg hICAM ODN in 1.0 ml citrate bu¡er, pH 4.0
containing varying concentrations of ethanol, as described in
Section 2. Lipid (E) and ODN (F) loss during particle size re-
duction (extrusion) was determined by both radiolabel and
HPLC analysis and gave comparable results.
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added to the ODN solution used to rehydrate the
lipid ¢lms. As lipid vesicles are able to form even
in relatively high concentrations of ethanol [39], we
speculated that the presence of this solvent might
increase the deformability of the DNA/lipid par-
ticles; thereby, facilitating the self-assembly and
size reduction processes. In the presence of increasing
concentrations of ethanol, the encapsulation e⁄-
ciency increased in a near-linear manner (Fig. 1A).
Residual alcohol was readily removed by dialysis.
Optimal processing occurred at 40% ethanol, with
rapid extrusion times and minimal losses of lipids
and ODN (6 3%) during size reduction (Fig. 1B).
At higher ethanol concentrations (s 50%), signi¢-
cant and visible aggregation and precipitation was
observed. At this ethanol concentration, some
ODN was lost through precipitation very early in
the formulation process (Fig. 1B); however, no addi-
tional losses of ODN were observed following dialy-
sis and anion-exchange chromatography, indicating
complete encapsulation of the residual ODN. At
lower ethanol concentrations, the particles were less
deformable and more ODN adsorbed to the surface
of the vesicles and was subsequently lost following
charge neutralization of the DODAP, dialysis and
anion-exchange chromatography. Given the positive
impact of ethanol on the ease of formulation and
sample recovery, the process was subsequently fur-
ther simpli¢ed in that the requisite lipid mixture was
dissolved in 100% ethanol and added to ODN dis-
solved in citrate bu¡er, pH 4.0 (2/3, v/v, ethanol/cit-
rate). This modi¢cation eliminated the requirement
for lipid ¢lms and greatly reduced sample processing
times.
In the absence of a steric barrier lipid, extensive
aggregation and fusion was observed upon addition
of the cationic lipid mixture to ODN at ¢nal ethanol
concentrations s 20% (v/v). The addition of PEG-
CerC14 lipid to the formulation at 10 mol% (with
respect to total lipid) eliminated this phenomenon,
consistent with the known role of PEG-lipid in pre-
venting the aggregation and fusion between lipid
vesicles [40]. An examination of the minimum quan-
tity of PEG-lipid required to form stable particles
indicated that wholesale aggregation and fusion
was prevented at v 5% PEG-lipid. Given the rela-
tively short chain length of the PEG-CerC14 hydro-
phobic anchor, there was the possibility that some
PEG-lipid may be lost during prolonged dialysis
through the dissociation of PEG-lipid monomers
from the vesicle membrane. To evaluate this and to
monitor the fate of the formulation components dur-
ing the preparation process, HPLC analyses were
performed at various stages during the formulation
process.
In a typical formulation consisting of DSPC/CH/
DODAP/PEG-CerC14 at a theoretical initial lipid
concentration of 10 mg/ml (total lipid), individual
lipid concentrations were determined to be 2.40,
4.97, 2.61 and 1.12 mg/ml, respectively (11.1 mg/ml
total lipid; 150 ml formulation volume). In the ¢nal
preparation following dialysis and concentration,
these lipid concentrations were observed to be 3.68,
7.33, 4.14 and 1.74 mg/ml, respectively (16.9 mg/ml
total lipid; 91 ml ¢nal volume), indicating that very
little loss of lipid components occurs during the for-
mulation process. Total lipid recovery was 92.4%.
However, sucrose density gradient isolation of
SALP prepared at high ODN to lipid ratios and
containing [14C]CHE and [3H]PEG-CerC14 markers
indicated that s 60^70% of the initial PEG-lipid was
excluded from the ¢nal vesicles and probably exists
Fig. 2. In£uence of aminolipid (DODAP) content on encapsula-
tion of ODN in SALP. SALP were prepared by the addition of
an ethanol solution containing lipid to hICAM ODN in citrate
bu¡er, pH 4.0, as described in Section 2. The mol% DODAP
was varied at the expense of DSPC. The CH and PEG-CerC14
contents were held constant at 45 mol% and 10 mol%, respec-
tively. The indicated mol% are with respect to all (total) lipid
components. The actual DODAP content (mol%) in each sam-
ple was determined by HPLC analysis as described in Section
2. The data points represent the mean þ S.D. of four experi-
ments.
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as PEG-lipid micelles, since no PEG-lipid was lost
during the dialysis step.
3.3. In£uence of DODAP on encapsulation e⁄ciency
The optimal DODAP concentration for formula-
tion was determined in DSPC/CH/DODAP/PEG-
CerC14 vesicles in the presence of 40% ethanol,
2 mg/ml ODN and 10 mg/ml total lipid. The mol%
DODAP in the formulation was varied at the ex-
pense of DSPC. As shown in Fig. 2, encapsulation
e⁄ciency increased from 5 to 80% as the concentra-
tion of DODAP was increased from 0 to 30 mol%.
In formulations with DODAP concentrations greater
than 30 mol%, vesicle size reduction became more
di⁄cult. This phenomenon was not observed in the
absence of ODN and was therefore most likely a
consequence of enhanced DODAP/ODN interactions
that resulted in an increased charge ratio ( þ ) and the
formation of larger particles. Consequently, 20^
25 mol% DODAP was considered to be an optimal
concentration for further characterization. The in£u-
ence of pH on ODN encapsulation was evaluated
employing a lipid composition consisting of DSPC/
CH/DODAP/PEG-CerC14 (25/45/20/10), 40% etha-
nol in citrate bu¡er, 2 mg/ml ODN and 10 mg/ml
total lipid. The encapsulation e⁄ciency increased
from 5 to s 90% as the pH was decreased through
the pK range of DODAP, pH 7 to pH 4 (Fig. 3).
Under the conditions employed in this study (180
mM citrate bu¡er, pH 4.0 and 25 mol% DODAP),
the apparent pKa of DODAP was determined to be
5.8 by measuring the bulk proton concentration in
the absence of ethanol as outlined in Bailey et al.
[38]. These results highlight the importance of elec-
trostatic interactions in the formulation process and
indicate that at physiological pH the formulation
would have little residual surface charge.
One concern in formulating ODN at acidic pHs
was the potential loss of purine bases through hydro-
lysis. PS ODN was therefore incubated at pH 4 and
65‡C and analyzed by mass spectrometry and HPLC.
The levels of depurination detected following a 2 h
incubation were less than 3%. A typical laboratory
scale formulation can be prepared in less than 30 min
with undetectable levels of degradation. For larger
scale formulations where processing times may in-
crease to several hours, solutions are only raised to
65‡C when necessary, thereby limiting depurination
to 6 0.5%. After encapsulation of ODN and adjust-
ment of the external pH to 7.6, the transmembrane
Fig. 3. pH Dependence of ODN encapsulation in SALP. ODN
was encapsulated in DSPC/CH/DODAP/PEG-CerC14 (20/45/25/
10, mol/mol/mol/mol) vesicles upon addition of an ethanol solu-
tion containing lipid to hICAM ODN in citrate bu¡er, as de-
scribed in Section 2. The measured pH of the bu¡er in the ab-
sence of ethanol, ODN and lipid is indicated (b). The data
points represent the mean þ S.D. of three experiments.
Fig. 4. Optimization of ODN to lipid ratios in SALP (A) and
by passive encapsulation in EPC:CH liposomes (B). ODN was
encapsulated in DSPC/CH/DODAP/PEG-CerC14 (20/45/25/10,
mol/mol/mol/mol) vesicles upon addition of an ethanol solution
containing lipid to varying concentrations of hICAM ODN in
citrate bu¡er containing 40% ethanol, as described in Section 2.
Alternatively, ODN was entrapped in 100 nm EPC/CH (55/45,
mol/mol) liposomes by passive encapsulation techniques. The
lipid concentrations in these instances were 50 mg/ml (20 mg/ml
ODN) and 250 mg/ml (200 mg/ml ODN). The encapsulation
e⁄ciency (b) and resulting ODN to lipid ratios (a) are indi-
cated. The data points represent the mean þ S.D. of three ex-
periments.
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pH gradient, measured by the distribution of methyl-
amine [41], indicated an internal pH of 5.5^6.0.
3.4. Optimization of ODN to lipid ratios
At a constant lipid concentration of 10 mg/ml total
lipid, the ¢nal ODN to lipid ratio was varied from
0.08 to 0.25 (w/w) by increasing the initial ODN
concentrations from 1 to 10 mg/ml (Fig. 4A). As
the ¢nal ODN to lipid ratio increased, a concomitant
decrease in the encapsulation e⁄ciency from 90^95%
to 25^30% was observed. Through this range, the
ODN to lipid ratio increased from 0.1 to 0.25. Stan-
dardized conditions for ODN encapsulation (2.0^2.5
mg/ml ODN and 10 mg/ml total lipid) were chosen
that typically yield 65^75% encapsulation with an
ODN to lipid ratio of 0.15^0.20 (w/w). In compari-
son, under the same conditions of lipid and antisense
concentration, the hydration of a dry lipid ¢lm com-
posed of EPC:CH would yield an encapsulation e⁄-
ciency of approximately 3% and an ODN to lipid
ratio of 0.002 [21]. Increasing the lipid concentration
(50 and 250 mg/ml) in this EPC:CH system resulted
in modest increases in encapsulation e⁄ciencies and
ODN to lipid ratios, but even at the highest lipid
concentration the resulting encapsulation e⁄ciency
and ODN to lipid ratios were only 14% and 0.08,
respectively (Fig. 4B).
The DODAP formulation process appears to be
independent of ODN sequence, has been tested for
PS ODN varying in length from 15 to 24 bases and is
applicable to phosphodiester ODN, synthetic ribo-
zymes, and plasmid DNA (Maurer et al., manuscript
in preparation). We refer to the ODN-loaded vesicles
produced by this procedure as SALP.
3.5. Protection of ODN from nuclease degradation
It is important to demonstrate that the ODN in
SALP is indeed encapsulated within the lipid vesicles
and not simply adsorbed to the vesicle surface. To
demonstrate protection from extracellular nucleases,
aliquots of free and encapsulated ODN were incu-
bated with excess fungal S1 nuclease for various
times, in the presence or absence of Triton X-100.
Free PS ODN was completely degraded in less
than 5 min while no detectable degradation was ob-
served for up to 24 h for the encapsulated ODN (Fig.
5). This protection was lost following the addition of
detergent to solubilize the lipid bilayer, strongly sug-
gesting that the ODN was encapsulated.
3.6. Evaluation of ODN encapsulation by 31P NMR
Since SALP contain a PEG surface coating that
may sterically shield the surface of vesicles from nu-
clease activity, 31P NMR was used to con¢rm that
the ODN was encapsulated in the interior of the
Fig. 5. Nuclease protection of ODN. Encapsulation and protection of ODN was initially demonstrated using a nuclease protection as-
say. Free ODN or SALP were incubated with 100 U of S1 nuclease in the presence or absence of 1% Triton X-100. At the indicated
times, aliquots of the incubation mixture were removed and analyzed for ODN integrity as outlined in Section 2.
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vesicles. All of the spectra shown were obtained from
samples containing the same concentration of c-myc
ODN (2.0 mg/ml) (Fig. 6). When c-myc ODN was
free in solution, a sharp 31P NMR signal was de-
tected (spectrum 1), however, the signal from the
same concentration of c-myc ODN encapsulated in
SALP (spectrum 2) was broadened beyond detection
under the spectrometer conditions employed (see
Section 2). These data can be explained if the en-
trapped ODN is bound to the interior membrane
surface through electrostatic interactions with the
cationic form of DODAP, and therefore immobilized
on the NMR time-scale. The aqueous core of the
SALP is pH 5.5^6.0, a range in which a large pro-
portion of DODAP molecules will be positively
charged. When this transmembrane pH gradient is
collapsed and equilibrated to pH 7.4 by the addition
of 150 mM ammonium acetate and NaOH to the
external bu¡er, a 31P NMR signal for the ODN be-
came apparent (spectrum 3). This is consistent with
the neutralization of DODAP and subsequent release
of ODN from the membrane surface and into solu-
tion where its motion can be detected. The ¢nal three
spectra demonstrate that the signal shown in spec-
trum 3 arises from c-myc PS ODN encapsulated in-
side the SALP. The addition of 5 mM MnSO4, a
membrane impermeable NMR line-broadening re-
agent, had no e¡ect on the signal intensity until the
sample was solubilized in 200 mM OGP, after which
the 31P signal was eliminated (spectra 4 and 5, re-
spectively). However, in the absence of MnSO4, sol-
ubilization in detergent at pH 7.4 produced two
sharp 31P NMR signals, one from c-myc PS ODN
free in solution and the other arising from phospho-
lipids in detergent micelles (spectrum 6).
The 31P NMR signal intensities for ODN shown in
spectra 1 and 6 were the same, however, the signal
from the same concentration of encapsulated ODN
was attenuated by about 40% (spectra 3 and 4). This
was not due to NMR resonance saturation because
the spin-lattice relaxation times (T1) of free (T1 =
1.7 s) and encapsulated (T1 = 2.1 s) ODN at pH 7.4
were essentially the same. The T1 values were mea-
sured by an inversion-recovery pulse sequence on
samples 1 and 3. Furthermore, the interpulse delay
of 3 s for 50‡ pulses allows for complete relaxation of
all ODN resonances. The attenuation of signal inten-
sity shown in spectra 3 and 4 can be attributed to
several possibilities, including incomplete solubility
of the encapsulated ODN in the aqueous core of
the particle, or the existence of secondary ODN-lipid
structures within SALP.
3.7. Evaluation of SALP by cryo-electron microscopy
Freeze-fracture electron microscopy and quasi-
elastic light scattering (QELS) indicated that SALP
were composed of a homogeneous population of
vesicles with a mean diameter of 110 þ 30 nm. The
vesicle size distribution was stable for at least
6 months during storage at 4‡C. To investigate the
potential existence of secondary structures within
SALP, a cryo-electron microscopy analysis of
SALP was performed at two di¡erent ODN to lipid
ratios (0.025 and 0.25, w/w) and revealed several in-
teresting structural features (Fig. 7). At the higher
ODN to lipid ratio, the SALP preparation consisted
of spherical vesicles, with populations of LUV and
small multilamellar vesicles (SMLV) (Fig. 7, bottom
panel). The average particle sizes were the same as
Fig. 6. 31P NMR determination of ODN encapsulation. Encap-
sulation of PS c-myc ODN was assessed using a 31P NMR as-
say as described in Section 2 and in the text. The individual
spectra represent: (1) free ODN in HBS, pH 7.4; (2) ODN en-
capsulated in SALP exhibiting interior pHV5.5/exterior pH
7.4; (3) sample 2 with the interior pH raised to 7.4 using
150 mM ammonium acetate; (4) sample 3 with 5 mM MnSO4
added to the exterior of SALP; (5) sample 4 with 200 mM oc-
tyl-L-D-glucopyranoside (OGP) added to solubilize SALP; and
(6) SALP solubilized by 200 mM OGP. All samples contained
2.0 mg/ml ODN. All spectral intensities corresponding to 800
scans were normalized to 2.0 mg/ml antisense. Integrated signal
intensities ( þ 0.05 mg/ml) in mg/ml are: 2.00 (1); 0.00 (2); 1.24
(3); 1.24 (4); 0.00 (5); 2.00 (6). T1 values, 1.7 s (1); 2.1 s (3).
Chemical shifts are referenced to external 85% H3PO4.
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determined previously by freeze-fracture and QELS
analyses. The SMLV consisted of numerous lamellae
(typically 6^9) arranged as concentric rings inside the
particle core such that the innermost structures ex-
hibit diameters as small as 20 nm (Fig. 7, bottom
panel). In general the encapsulated membrane struc-
tures are closely associated; however, many of the
particles share a common feature where the outer
2^4 lamellae at one side of the particle appear to
separate (Fig. 7, bottom panel). Interestingly, at the
low ODN to lipid ratio SALP are predominantly
unilamellar, but most exhibit a cap-like structure
(Fig. 7, top panel, arrow) that may represent the
interaction between two vesicles and could be a
pre-cursor to the SMLV structures observed at high-
er ODN to lipid ratios. The SMLV structures of
Fig. 7. Cryo-electron microscopy of SALP. The structure of SALP was evaluated at low (top panel) and high (bottom panel) initial
ODN to lipid ratios (0.025, w/w and 0.25, w/w, respectively). Magni¢cation in each panel was 50 000U. The scale is represented by
the bar (50 nm).
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SALP observed in Fig. 7 suggest a constrained mo-
bility of antisense between the lipid bilayers, possibly
explaining the reduced NMR signal described above.
3.8. Pharmacokinetics of SALP
The plasma circulation pro¢le of SALP, contain-
ing a [3H]thymidine labeled ODN, was monitored in
ICR mice after i.v. administration at a dose of ap-
proximately 100 mg lipid/kg body weight (15 mg
ODN/kg body weight). To highlight the importance
of the aminolipid on the circulation times, SALP
formulations containing ionizable and quaternary
aminolipids were investigated. In addition, these for-
mulations contained either PEG-CerC14 or PEG-
CerC20. The PEG-CerC14 lipid is able to rapidly
di¡use out of the lipid bilayer, with an in vitro
half-life of V1.1 h [42]. Under the same conditions,
the exchange rate of the PEG-CerC20 is much slower
(V13 days), and this lipid is therefore able to pro-
vide steric protection against interaction with plasma
proteins and allow extended circulation times com-
parable to classical sterically stabilized liposomes
containing PEG2000-DSPE [28,43].
SALP containing DODAP and either PEG-CerC14
or PEG-CerC20 exhibited monophasic plasma elimi-
nation pro¢les and half-lives (t1=2V5^6 h and 10^12
h, respectively) that were signi¢cantly longer than the
circulation half-life of free PS ODN (t1=2 5^10 min)
(Fig. 8). In contrast, when SALP contained a quater-
nary aminolipid (DODAC), the plasma elimination
pro¢les were much more rapid. Formulations con-
taining DODAC and either PEG-CerC14 or PEG-
CerC20 exhibited half-lives of approximately 15 min
and 2^3 h, respectively. This di¡erence likely re£ects
the ability of PEG-CerC20 to inhibit the interactions
between the predominantly anionic plasma proteins
and the cationic lipid vesicles, thereby reducing op-
sonization and increasing the plasma residence time
of the formulation [43]. Rapid plasma elimination
(t1=26 5 min) was also observed for DOPE/DODAC
(1/1)/ODN lipoplexes administered at lipid doses
comparable to the SALP formulations.
4. Discussion
E¡ective, systemic delivery systems for DNA and
RNA are considered basic to the successful clinical
application of gene-based drugs [4,44^46]. In this
study, we describe and characterize a novel lipid-
based formulation (SALP) designed for i.v. delivery
of polyanionic oligonucleotides. The formulation
process represents a signi¢cant improvement over ex-
isting methods as ODN are encapsulated with both
high e⁄ciency and high drug to lipid ratios, while
employing simple manufacturing techniques.
Other lipid mixtures and encapsulation protocols
have been applied to oligonucleotides with varying
degrees of success. Standard methods, employing
net neutral lipid mixtures, yield low encapsulation
e⁄ciencies and drug to lipid ratios (reviewed in
[20,21]). This can be overcome by incorporating cat-
ionic lipids into the formulation, but the resulting
lipid/nucleic acid complexes are typically unstable
and exhibit limited circulation times [22^24]. For ex-
ample, Gokhale et al. have recently described a lipo-
somal formulation composed of PC/CH/DDAB (55/
28/17, mol/mol/mol) and raf-1 ODN that sensitizes
radioresistant SQ-20B xenografted tumors to ioniz-
Fig. 8. Circulation pro¢les in mice. The in£uence of surface
charge and presence of a steric polymer surface coating on the
circulation of SALP was evaluated upon i.v. administration in
ICR mice. Formulations contained 3H-labeled mICAM ODN
and were administered at ODN doses of 15 mg/kg and approxi-
mate lipid doses of 100 mg/kg body weight. Formulations eval-
uated were: DSPC/CH/DODAP/PEG-CerC20 (b), DSPC/CH/
DODAP/PEG-CerC14 (a), DSPC/CH/DODAC/PEG-CerC20
(F), DSPC/CH/DODAC/PEG-CerC14 (E), DODAC/dioleoyl-
phosphatidylethanolamine (DOPE) (1/1)/ODN complexes (8),
and free ODN (R). Except where indicated, the lipid ratios
were 20/45/25/10 (mol/mol/mol/mol). The data points represent
the mean þ S.D. from ¢ve animals.
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ing radiation [23]. However, only V1% of the total
administered dose remained in the circulation at
5 min post-administration. Moreover, in this type
of system, signi¢cant quantities of oligonucleotide
would be expected to remain associated with the
positively charged surface of the particles and disso-
ciate from the carriers in the blood. The MVE ap-
proach employed by Thierry et al. [47,48] generates
high encapsulation e⁄ciencies (comparable to SALP)
and drug to lipid ratios (approximately 2^4-fold low-
er than SALP). However, the formulation employs
3^7 mol% cardiolipin (CL), a potent activator of rat
and human complement [25,26]. Furthermore, simi-
lar liposome formulations (EPC/CH/CL, 45/45/10)
containing CL have been shown to exhibit very short
circulation times, therefore the clinical application of
this formulation would be expected to be limited [49].
Another approach to improving encapsulation has
been to chemically modify oligonucleotides, making
them more lipophilic [44,50]. However, these mole-
cules are insoluble in aqueous environments which,
until recently, has limited their clinical development
[51].
While nuclease protection assays and 31P NMR
studies indicate that ODN is encapsulated within
SALP, the mechanism of SALP formation and
ODN entrapment is not fully understood. In this
regard, Huebner et al. recently observed the forma-
tion of compact multilamellar structures when frag-
mented, linear genomic DNA (average 6000 bp) was
added to unilamellar cationic vesicles composed of
DMPC/DC-Chol (3:2, molar ratio) [52]. Employing
cryo-electron microscopy, these authors showed
structures that resemble the tightly associated, con-
centric bilayers presented in Fig. 7 (bottom panel).
To explain their results, they present a model in
which vesicles, coated with an adsorbed layer of
DNA, are forced into close contact with neighboring
vesicles through electrostatic interactions. The
vesicles become £attened and deformed in the con-
tact region with DNA sandwiched between the mem-
branes. Changes in lipid packing resulting from lat-
eral separation of lipids and a reduction of
headgroup area induced by the charge neutralization
of DC-Chol by DNA are proposed as two factors
that contribute to the destabilization of vesicles caus-
ing them to fuse and/or rupture. Sequential binding,
£attening and rupture of vesicles are presented as a
mechanism for the formation of the highly compact
multilamellar structures.
Although there are signi¢cant di¡erences between
the DNA/lipid structures described by Huebner et al.
[52] and SALP, the mechanism by which the two
form may be related. Spontaneous formation of
small unilamellar vesicles is expected to occur upon
rapid dilution of the ethanol-lipid solution in aque-
ous bu¡er [53]. The negatively charged ODN will
interact with the cationic vesicles and lateral separa-
tion of the cationic form of DODAP, facilitated by
high ethanol concentration, could lead to the forma-
tion of membrane patches enriched with DODAP
and depleted of PEG. This hypothesis is supported
by the observation that s 60^70% of the initial
PEG-lipid was excluded from the ¢nal vesicles.
Therefore, the distended bilayers observed in each
of the SMLVs may re£ect areas in which PEG-lipids
have concentrated due to lateral separation e¡ects
(Fig. 7). The structural features of SALP and the
mechanisms of formation are currently under further
investigation.
It is interesting to note that for SALP containing
25 mol% DODAP, an ODN to lipid ratio (w/w) of
0.1 is su⁄cient for complete charge neutralization,
assuming all the cationic lipid is ionized and each
ODN base carries a net negative charge at the load-
ing pH. Therefore, to achieve ratios greater than this
suggests that the electrostatic interaction between
DODAP and the ODN bases is not stoichiometric
under the formulation conditions. At pH 4.0 it is
expected that s 99% of the DODAP molecules will
carry a positive charge. However, the net negative
charge on the ODN may be less than expected, based
on the number of bases, when the pK values of the
phosphates (pK 3^3.5) and protonation of bases such
as cytosine (pKV4.6) are taken into consideration.
Therefore, a reduction in net negative charge per
ODN molecule may account for the loading stoichi-
ometry observed for SALP with ODN to lipid ratios
(w/w) s 0.1.
The ionizable lipid and the PEG-Cer molecules
used to construct SALP endow this system with
unique features. The ionizable cationic lipid DODAP
facilitates e⁄cient charge-dependent loading at acidic
pH values, but also allows SALP to exhibit a near-
neutral surface charge at physiological pH. As a re-
sult, SALP can achieve extended circulation lifetimes
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following i.v. administration and would be expected
to exhibit preferential accumulation at disease sites
such as tumors and sites of in£ammation [54,55]. In
addition, the neutral form of DODAP has been
shown to induce fusion in model membrane systems
[38] and consequently may promote fusion on inter-
action of SALP with cell membranes, thereby en-
hancing intracellular delivery of ODN. However,
there is no direct evidence at this time that this ac-
tually occurs. With regard to the PEG-CerC14 or
PEG-CerC20 constituents, which are required to sta-
bilize SALP during formulation, it should be noted
that PEG coatings inhibit vesicle^vesicle and vesicle^
membrane association and fusion [40], and thus
would be expected to inhibit intracellular delivery
of ODN after reaching the disease site. However,
the PEG-CerC14 species exhibits a half-time for dis-
sociation from lipid vesicles in vivo of 3^6 min (Sem-
ple et al., manuscript submitted) following i.v. ad-
ministration and therefore would not be associated
with SALP when the particles reached a disease site.
Recently, Stuart et al. have demonstrated that lipid/
ODN particles prepared by a reverse-phase tech-
nique, in which the cationic lipid becomes seques-
tered in the inner monlayer of the vesicles during
preparation thereby minimizing external surface
charge, had long circulation times in vivo and re-
duced the expression of P-glycoprotein in multi-
drug-resistant human B-lymphoma cells in vitro
[56,57]. These results con¢rm that the general strat-
egy of reducing surface charge in lipid-based formu-
lations of ODN is practical and may be important in
the development of clinically viable systemic in vivo
delivery systems for antisense ODN.
In summary, we believe SALP represent a safe and
practical means to radically alter the pharmacoki-
netic characteristics of anionic antisense drugs and
overcome many of the drawbacks associated with
the clinical development of PS ODN and lipid-based
formulations thereof. As such, we are currently in-
vestigating the biochemical and pharmacological ac-
tivity of SALP formulations containing ODN speci¢c
for anti-in£ammatory (ICAM-1) and oncology-based
(c-myc and c-myb proto-oncogenes) targets. Studies
thus far indicate that SALP containing entrapped
ODN potentiate a range of desirable biological ef-
fects in vivo; including both antisense-speci¢c and
non-speci¢c e¡ects (enhanced activation of NK cells,
monocytes/macrophages and cytokines). Moreover,
we believe that this type of delivery system will be
broadly applicable to other DNA- and RNA-based
therapeutic agents and that, by choosing an appro-
priate ionizable lipid, it will be possible to encapsu-
late a wide variety of charged compounds, including
proteins, peptides, and other diagnostic and thera-
peutic agents. Finally, the unique SMLV structures
observed in this study provide further insight into the
interactions of DNA with cationic lipids and lipid
membranes and may aid in the design of more e¡ec-
tive delivery systems for nucleic acid therapeutics.
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